Business Context and Reporting Period
Spyre Therapeutics, Inc. (SYRE), a biopharmaceutical company focused on inflammatory bowel disease and rheumatic diseases, filed a Form 8-K on October 13, 2025. The report details the entry into a material definitive agreement for a public offering of common stock.
Key Financial Metrics
- Offering Size: 14,864,865 shares of common stock initially offered, plus a full exercise of the 30-day option for an additional 2,229,729 shares.
- Offering Price: $18.50 per share.
- Gross Proceeds: Approximately $316.2 million (before underwriting discounts, commissions, and estimated offering expenses).
- Closing Date: October 15, 2025.
- Net Proceeds: The filing text does not provide a clear value for net proceeds after deducting expenses.
Material Changes
The primary material change is the significant increase in liquidity through the equity offering. The company raised approximately $316.2 million in gross proceeds to fund its operations. This represents a substantial capital infusion compared to prior periods, though specific comparative financial metrics (revenue, profit, cash flow) are not included in this specific 8-K filing.
Guidance, Outlook, and Management Commentary
Management intends to use the net proceeds to advance programs in inflammatory bowel disease and rheumatic diseases. Specific allocations include:
- Funding preclinical studies and clinical trials.
- Manufacturing activities.
- Phase 3 readiness activities for antibody programs.
- Working capital and general corporate purposes.
The offering was conducted pursuant to a shelf registration statement (Form S-3) filed in February 2025. The underwriters were Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC, and Stifel, Nicolaus & Company, Incorporated.
Investor Verification Checklist
- Verify the exact amount of underwriting discounts and commissions to calculate the final net proceeds.
- Confirm the updated cash balance and runway following the closing of the offering on October 15, 2025.
- Review the specific timeline for Phase 3 readiness activities mentioned in the use of proceeds.
- Check for any dilution impact on existing shareholders given the issuance of approximately 17.1 million total shares.